Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
For a patient with well differentiated de novo metastatic breast cancer, triple positive breast cancer who did not respond to THP, do you go through all available HER2 targeted options before endocrine therapy?
Related Questions
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?
What strategies do you implement to control the nausea from Enhertu?
In metastatic hormone receptor positive breast cancer, would you consider combination exemestane and CDK4/6 inhibitor if letrozole and anastrazole are not tolerated?
When should paclitaxel (or other chemo) be discontinued in de novo metastatic triple negative breast cancer with high PDL1 in favor of continuing pembrolizumab alone with good treatment response?
Do you have a preference of denosumab over zoledronic acid in patients with metastatic breast cancer with osseous involvement with normal renal function?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
What are your top takeaways from SABCS 2023?
How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?
Do you start systemic therapy for patients with previously localized HR+ positive breast cancer developing solitary bone metastasis which is now triple negative if there is no other site of disease after localized radiation?
